SINGAPORE (June 25): Medical technology company Biolidics has entered into a partnership with Zhongshan TopGene Medical Laboratory Co to develop and commercialise laboratory-developed tests (LDTs) in the field of circulating tumour cells (CTCs) using Biolidics' ClearCell FX1 System and CTChip FR1 biochip.

Have a premium account? Sign in to continue reading.

Unlimited access to all stories from $4.99/month*

The latest reporting and analysis from business and investments to news and views on social issues.

Bonus:

  • Simultaneous logins across all devices
  • Instant access to past digital issues
  • Unlimited access to The Edge Malaysia
  • *For annual subscription plan only. T&Cs apply

SUBSCRIBE NOW